Glutaminyl Cyclase Inhibitor 1 is primarily used in research to study its role in modulating enzyme activity, particularly in neurodegenerative diseases. It has shown potential in reducing the formation of harmful pyroglutamate-modified proteins, which are associated with conditions like Alzheimer's disease. This compound is also explored for its therapeutic applications in targeting inflammation and immune responses, as glutaminyl cyclase plays a role in these processes. Additionally, it aids in understanding the biochemical pathways involved in protein modification and aggregation, contributing to the development of novel treatments for chronic diseases.